The innovative flow-through solution for continuous viral inactivation

Authors

• Johannes Wortmeyer, Sartorius, GermanyFollow
• Stuart Tindal, Sartorius Stedim Biotech GmbH
• Karolina Meyer-Heinrichs, Sartorius Stedim Biotech GmbH
• Lisa Lipski, Sartorius Stedim Biotech GmbH
• Tobias Steinwedel, Sartorius Stedim Biotech GmbH
• Chad Varner, Global CMC Development, Sanofi, USA
• Kevin Brower, Global CMC Development, Sanofi, USA
• Michael Coolbaugh, Global CMC Development, Sanofi, USA
• Akshat Mullerpatan, Global CMC Development, Sanofi, USA
• Vishwanath Hebbi, Merck & Co., Inc. Process Research & Development, Rahway, NJ, USA
• Mark Brower, Merck & Co., Inc. Process Research & Development, Rahway, NJ, USA
• Lara Fernandez Cerezo, Merck & Co., Inc. Process Research & Development, Rahway, NJ, USA
• Adrian Gospodarek, Merck & Co., Inc. Process Research & Development, Rahway, NJ, USA
• Nuno Pinto, Merck & Co., Inc. Process Research & Development, Rahway, NJ, USA

Conference Dates

October 5-9, 2025

Abstract

viral inactivation | plug flow reactor I residence time | flow-through

Recommended Citation

Johannes Wortmeyer, Stuart Tindal, Karolina Meyer-Heinrichs, Lisa Lipski, Tobias Steinwedel, Chad Varner, Kevin Brower, Michael Coolbaugh, Akshat Mullerpatan, Vishwanath Hebbi, Mark Brower, Lara Fernandez Cerezo, Adrian Gospodarek, and Nuno Pinto, "The innovative flow-through solution for continuous viral inactivation" in "Integrated Continuous Biomanufacturing VII (ICB VII)", Irina Ramos, AstraZeneca; Mark Brower, Merck; Alois Jungbauer, BOKU; K. Brower, Sanofi Eds, ECI Symposium Series, (2025). https://dc.engconfintl.org/biomanufact_vii/17